| Trial ID: | L1973 |
| Source ID: | NCT06226727
|
| Associated Drug: |
Br1019
|
| Title: |
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus|Essential Hypertension
|
| Interventions: |
DRUG: BR1019|DRUG: BR1019-1|DRUG: BR1019-2
|
| Outcome Measures: |
Primary: AUCτ, Area under the concentration-time curve from time zero to time τ, 0-48 hours after administration|Cmax, Maximum concentration of drug in plasma, 0-48 hours after administration |
|
| Sponsor/Collaborators: |
Sponsor: Boryung Pharmaceutical Co., Ltd
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
52
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-02-14
|
| Completion Date: |
2024-03-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-04-02
|
| Locations: |
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, 08779, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT06226727
|
